Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Amyotrophic Lateral Sclerosis

In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Amyotrophic Lateral Sclerosis

Ryan G. Brotman et al.
Free Books & Documents

Excerpt

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive, paralytic, neurodegenerative disease affecting the upper and lower motor neurons. ALS is the most common motor neuron disease (MND) and has both sporadic and familial forms. Previously, ALS was distinguished from other motor neuron diseases (ie, primary lateral sclerosis, primary muscular atrophy, and progressive bulbar palsy) based on where the patient's first symptoms presented. It is now recognized that ALS presents with diverse clinical heterogeneity. The etiology of ALS is unknown. Numerous possible genetic and sporadic possibilities are suggested. Amyotrophic lateral sclerosis most commonly begins with signs of LMN degeneration affecting the upper extremity but can also present as UMN or bulbar symptoms. Eventually, affected patients will experience respiratory paralysis and, inevitably, death. There is no cure for ALS; however, multiple medications and interventions can help reduce symptoms and improve their quality of life.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Ryan Brotman declares no relevant financial relationships with ineligible companies.

Disclosure: Maria Moreno-Escobar declares no relevant financial relationships with ineligible companies.

Disclosure: Joe Joseph declares no relevant financial relationships with ineligible companies.

Disclosure: Sunil Munakomi declares no relevant financial relationships with ineligible companies.

Disclosure: Gauri Pawar declares no relevant financial relationships with ineligible companies.

References

    1. Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017 Jul 13;377(2):162-172. - PubMed
    1. Alves I, Gromicho M, Oliveira Santos M, Pinto S, Pronto-Laborinho A, Swash M, de Carvalho M. Demographic changes in a large motor neuron disease cohort in Portugal: a 27 year experience. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Jun 09;:1-11. - PubMed
    1. Tzeplaeff L, Wilfling S, Requardt MV, Herdick M. Current State and Future Directions in the Therapy of ALS. Cells. 2023 May 31;12(11) - PMC - PubMed
    1. Margeta M. Neuromuscular disease: 2023 update. Free Neuropathol. 2023 Jan;4:2. - PMC - PubMed
    1. Quinn C, Elman L. Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases. Continuum (Minneap Minn) 2020 Oct;26(5):1323-1347. - PubMed

Publication types

LinkOut - more resources